Human Beta-glucuronidase mutants with elevated enzymatic activity under physiological conditions and method for identifying such
Docket Number:12A-970630
Inventor:Steve Roffler, Chia-Hung Wu, Wolfgang Schechinger,
IP Status:Issued US8,491,891、TWI396550
Abstract:
The mutant human β-glucuronidase developed here displays enhanced enzymatic activity at physiological pH. It activates glucuronide prodrugs more effectively than native glucuronidase. Selective targeting of this enzyme to tumors enhances treatment of cancer by glucuronide prodrugs. The mutant human β-glucuronidase may also be used to improve enzyme replacement therapy of β-glucuronidase deficient patients.
Fields of Application:
Cancer therapy, enzyme replacement therapy.
Advantages when compared to the existing technologies:
Compared to other enzymes employed for antibody-directed enzyme prodrug therapy, our enzyme displays high activity and low immunogenicity. Most prodrug-activating enzymes are derived from bacteria or viruses, which causes immune responses in humans so multiple administrations can not be given.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
IP Status:Issued US8491891、TWI396550
